Pharmaceutical Executive December 12, 2024
This acquisition will bring Aliada’s Alzheimer’s treatment under AbbVie’s pipeline.
AbbVie announced the completion of its acquisition of Aliada Therapeutics.1 As a result, Aliada’s lead investigational asset, ALIA-1758, is an Alzheimer’s treatment that’s in Phase 1 trials and will now fall under AbbVie’s pipeline.
In a press release, AbbVie vice president of neuroscience development Dawn Carlson, MD, MPH, said, “Alzheimer’s disease poses a significant public health challenge, impacting millions worldwide and is becoming more prevalent as populations age. With the acquisition now complete, we look forward to advancing potentially disease-modifying therapies such as ALIA-1758 for Alzheimer’s disease and bolstering our neuroscience discovery and development efforts by leveraging Aliada’s novel CNS drug delivery platform.”
AbbVie first announced its plans to acquire...